Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
-
Bahlis, Nizar J (University of Calgary)
;
Corso, A. (Policlinico San Matteo Universita di Pavia) ;
Mugge, L.O. (Universitätsklinikum Jena) ;
Shen, Z.X. (Shanghai Jiao Tong University) ;
Desjardins, Pierre (Hôpital Charles LeMoyne) ;
Stoppa, A.M. (Institut Paoli Calmettes) ;
Decaux, O. (CHRU Hôpital Sud Médecine Interne) ;
De Revel, T. (Hôpital d'Instruction des Armées PERCY) ;
Granell, Miquel (Institut d'Investigació Biomèdica Sant Pau) ;
Marit, G. (CHU de Bordeaux) ;
Nahi, H. (Karolinska Institutet (Suecia)) ;
Demuynck, H. (H. Hart Ziekenhuis Roeselare-Menen) ;
Huang, S.Y. (National Taiwan University Hospital (Taipei, Taiwan)) ;
Basu, S. (New Cross Hospital) ;
Guthrie, T.H. (21st Century Oncology) ;
Ervin-Haynes, A. (Celgene Corporation) ;
Marek, J. (Celgene Corporation) ;
Chen, G. (Celgene Corporation) ;
Facon, Thierry (CHRU Lille) ;
Universitat Autònoma de Barcelona
guest ::
Subscribe to this discussion. You will then receive all new comments by email.
